Improved therapeutic outcome following combination immunogene vaccination therapy in murine myeloma

Leukemia and Lymphoma

Volumn 44, Issue 10, 2003, Pages 1775-1784

  Li, Z H ^a   Wen, X Y ^a   Mandelbaum, S ^a   Falcioni, N ^a   Hawley, T S ^b   Hawley, R G ^b   Stewart, A K ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b HOLLAND LABORATORY   (United States)

Author keywords

CD80; Flt3; GM CSF; IL 12; Myeloma and gene therapy

Indexed keywords

B7 ANTIGEN; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENETIC ENGINEERING; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE STRAIN; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TREATMENT OUTCOME; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD80; CANCER VACCINES; CELL DIVISION; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; LIGANDS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, SCID; MULTIPLE MYELOMA; RETROVIRIDAE; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0141758488     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000119208     Document Type: Article

References (43)

1. Lokhorst, H.M., Schattenberg, A., Cornelissen, J.J., Thomas, L.L. and Verdonck, L.F. (1997) "Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation", Blood 90, 4206-4211.
2. Kwak, L.W., Taub, D.D., Duffey, P.L., Bensinger, W.I., Bryant, E.M., Reynolds, C.W. and Longo, D.L. (1995) "Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor", Lancet 345, 1016-1020.
3. Wen, Y-J., Ling, M. and Lim, S.H. (1998) "Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma", Br. J. Haematol. 100, 464-468.
4. Bergenbrant, S., Osterborg, A., Holm, G., Mellstedt, H. and Lefvert, A.K. (1991) "Anti-idiotypic antibodies in patients with monoclonal gammopathies: relation to the tumour load", Br. J. Haematol. 78, 66-70.
5. Bergenbrant, S., Yi, Q., Osterborg, A., Bjorkholm, M., Osby, E., Mellstedt, H., Lefvert, A.K. and Holm, G. (1996) "Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients", Br. J. Haematol. 92, 840-846.
6. Reichardt, V.L., Okada, C.Y, Liso, A., Benike, C.J., Stockerl-Goldstein, K.E., Engleman, E.G., Blume, K.G. and Levy, R. (1999) "Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study", Blood 93, 2411-2419.
7. Burton, J., Mishina, D., Cardillo, T., Lew, K., Rubin, A., Goldenberg, D.M. and Gold, D.V. (1999) "Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma", Clin. Cancer Res. 5(10 Suppl.), 3065s.
8. van Baren, N., Brasseur, F., Godelaine, D., Hames, G., Ferrant, A., Lehmann, F., Andre, M., Ravoet, C., Doyen, C., Spagnoli, G.C., Bakkus, M., Thielemans, K. and Boon, T. (1999) "Genes encoding tumor-specific antigens are expressed in human myeloma cells", Blood 94, 1156-1164.
9. Pellat-Deceunynck, C., Mellerin, M.P., Labarriere, N., Jego, G., Moreau-Aubry, A., Harousseau, J.L., Jotereau, F. and Bataille, R. (2002) "The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells", Eur. J. Immunol. 30, 803-809.
10. Katano, H., Iwasaki, T., Baba, N., Terai, M., Mori, S., Iwamoto, A., Kurata, T. and Sata, T. (2000) "Identification of antigenic proteins encoded by human herpesvirus 8 and seroprevalence in the general population and among patients with and without Kaposi's sarcoma", J. Virol. 74, 3478-3485.
11. Lang, D., Hinderer, W., Rothe, M., Sonneborn, H.H., Neipel, F., Raab, M., Rabenau, H., Masquelier, B. and Fleury, H. (1999) "Comparison of the immunoglobulin-G-specific seroreactivity of different recombinant antigens of the human herpesvirus 8", Virology 260, 47-54.
12. Goudsmit, J., Renwick, N., Dukers, N.H., Coutinho, R.A., Heisterkamp, S., Bakker, M., Schulz, T.F., Cornelissen, M. and Weverling, G.J. (2000) "Human herpesvirus 8 infections in the Amsterdam Cohort Studies (1984-1997): analysis of seroconversions to ORF65 and ORF73", Proc. Natl Acad. Sci. USA 97, 4838-4843.
13. Henry, F., Bretaudeau, L., Hequet, A., Barbieux, I., Lieubeau, B., Meflah, K. and Gregoire, M. (1999) "Role of antigen-presenting cells in long-term antitumor response based on tumor-derived apoptotic body vaccination", Pathobiology 67, 306-310.
14. Henry, F., Boisteau, O., Bretaudeau, L., Lieubeau, B., Meflah, K. and Gregoire, M. (1999) "Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines", Cancer Res. 59, 3329-3332.
15. Celluzzi, C.M. and Falo, L.D., Jr (1998) "Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection", J. Immunol. 160, 3081-3085.
16. Wang, J., Saffold, S., Cao, X., Krauss, J. and Chen, W. (1998) "Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines", J. Immunol. 161, 5516-5524.
17. Bannerji, R., Arroyo, C.D., Cordon-Cardo, C. and Gilboa, E. (1994) "The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity", J. Immunol. 152, 2324-2332.
18. Nishihori, H., Tsuji, H., Wang, H., Tahara, H., Akiyama, M., Ogawa, Y., Matsushima, K., Iwakura, Y. and Mukaida, N. (2000) "Participation of endogenously produced interferon gamma in interleukin 4-mediated tumor rejection", Hum. Gene Ther. 11, 659-668.
19. Dunussi-Joannopoulos, K., Runyon, K., Erickson, J., Schaub, R.G., Hawley, R.G. and Leonard, J.P. (1999) "Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity", Blood 94, 4263-4273.
20. Ichinose, Y, Okino, T., Yamasaki, S., Moriguchi, Y, Sugie, T., Li, L., Kanaoka, S., Kan, N., Watanabe, Y and Imamura, M. (1999) "Reduction of tumorigenicity by an interferon-gamma-gene-transduced tumor on another syngeneic tumor in a murine model", Surg. Today 29, 338-343.
21. Cayeux, S., Richter, G., Noffz, G., Dorken, B. and Blankenstein, T. (1997) "Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation", J. Immunol. 158, 2834-2841.
22. Chaperot, L., Plumas, J., Jacob, M.C., Bost, F., Molens, J.P., Sotto, J.J. and Bensa, J.C. (1999) "Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas", Exp. Hematol. 27, 479-488.
23. Labeur, M.S., Roters, B., Pers, B., Mehling, A., Luger, T.A., Schwarz, T. and Grabbe, S. (1999) "Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage", J. Immunol. 162, 168-175.
24. Kopantzev, E., Roschke, V. and Rudikoff, S. (1998) "Interleukin-2-mediated modulation of plasma cell tumor growth in a model of multiple myeloma", Hum. Gene Ther. 9, 13-19.
25. Lieu, F.H., Hawley, T.S., Fong, A.Z. and Hawley, R.G. (1997) "Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: implications for immune gene therapy", Cancer Gene Ther. 4, 167-175.
26. Turner, J.G., Tan, J., Crucian, B.E., Sullivan, D.M., Ballester, O.F., Dalton, W.S., Yang, N.S., Burkholder, J.K. and Yu, H. (1998) "Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model", Hum. Gene Ther. 9, 1121-1130.
27. Wendtner, C.M., Nolte, A., Mangold, E., Buhmann, R., Maass, G., Chiorini, J.A., Winnacker, E.L., Emmerich, B., Kotin, R.M. and Hallek, M. (1997) "Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response", Gene Ther 4, 726-735.
28. Shtil, A.A., Turner, J.G., Durfee, J., Dalton, W.S. and Yu, H. (1999) "Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes", Blood 93, 1831-1837.
29. Hawley, T.S., Linsley, P.S. and Hawley, R.G. (1998) "Coexpression of B7-1 with interleukin-12 enhances vaccine-induced antitumour immunity in experimental myeloma", Hematology 3, 365-374.
30. Hawley, T.S., Fong, A.Z.C., Griesser, H., Lyman, S.D. and Hawley, R.G. (1998) "Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand", Blood 92, 2003-2011.
31. Zhang, X.-G., Bataille, R., Jourdan, M., Saeland, S., Banchereau, J., Mannoni, P. and Klein, B. (1990) "Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells", Blood 76, 2599-2605.
32. Fearon, E.R., Pardoll, D.M., Itaya, T., Golumbek, P., Levitsky, H.I., Simons, J.W., Karasuyama, H., Vogelstein, B. and Frost, P. (1990) "Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor", Cell 60, 397-403.
33. McBride, W.H., Thacker, J.D., Comora, S., Economou, J.S., Kelley, D., Hogge, D., Dubinett, S.M. and Dougherty, G.J. (1992) "Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity", Cancer Res. 52, 3931-3937.
34. McAdam, A.J., Pulaski, B.A., Harkins, S.S., Hutter, E.K., Lord, E.M. and Frelinger, J.G. (1995) "Synergistic effects of co-expression of the Th1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells", Int. J. Cancer 61, 628-634.
35. Klugewitz, K., Scheffold, A., Radbruch, A. and Hamann, A. (2000) "Transfer of IFNgamma-depleted CD4(+) T cells together with CD8(+) T cells leads to rejection of murine kidney sarcoma in mice", Int. J. Cancer 87, 673-679.
36. Bodey, B., Bodey, Jr., B., Siegel, S.E. and Kaiser, H.E. (2000) "Failure of cancer vaccines: the significant limitations of this approach to immunotherapy", Anticancer Res. 20, 2665-2676.
37. Hawley, T.S., Lach, B., Burns, B.F., May, L.T., Sehgal, P.B. and Hawley, R.G. (1991) "Expression of retrovirally transduced IL-1 alpha in IL-6-dependent B cells: a murine model of aggressive multiple myeloma", Growth Factors 5, 327-338.
38. Lynch, D.H., Andreasen, A., Maraskovsky, E., Whitmore, J., Miller, R.E. and Schuh, J.C. (1997) "Flt3 ligand induces tumor regression and antitumor immune responses in vivo", Nat. Med. 3, 625-631.
39. Esche, C., Subbotin, V.M., Maliszewski, C., Lotze, M.T. and Shurin, M.R. (1998) "FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma", Cancer Res. 58, 380-383.
40. Chen, K., Braun, S., Lyman, S., Fan, Y., Traycoff, C.M., Wiebke, E.A., Gaddy, J., Sledge, G., Broxmeyer, H.E. and Cornetta, K. (1997) "Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model", Cancer Res. 57, 3511-3516.
41. Stewart, A.K., Lassam, N.J., Quirt, I.C., Bailey, D.J., Rotstein, L.E., Krajden, M., Dessureault, S., Gallinger, S., Cappe, D., Wan, Y., Addison, C.L., Moen, R.C., Gauldie, J. and Graham, F.L. (1999) "Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial", Gene Ther 6, 350-363.
42. Trudel, S., Li, Z., Dodgson, C., Nanji, S., Wan, Y., Voralia, M., Hitt, M., Gauldie, J., Graham, F.L. and Stewart, A.K. (2001) "Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma-A phase 1 study", Leukemia 15, 846-854.
43. Wen, X.-Y., Mandelbaum, S., Hitt, M., Graham, F.L., Li, Z.H., Hawley, T.S., Hawley, R.G. and Stewart, A.K. (2001) "Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: Studies in a myeloma model", Cancer Gene Ther. 8, 361-370.